D
Atossa Therapeutics, Inc. ATOS
$1.48 $0.0553.87%
Recommendation
Sell
Prev Close
$1.37
Volume
346,557
Avg Vol (90D)
1,278,717
Market Cap
$171.67M
Dividend & Yield
--
52-Week Range
$0.5901 - $2.31
P/E (TTM)
--
EPS (TTM)
-$0.2386
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug
4/15/2024 - Proactive Investors - UK
Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial
4/15/2024 - The Fly
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer
4/15/2024 - Globe Newswire
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
4/11/2024 - Zacks Investment Research
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
4/11/2024 - Globe Newswire
Atossa Therapeutics Poised for Growth with Promising Breast Cancer Treatment
4/10/2024 - TipRanks Financial Blog
Atossa Therapeutics reports positive data from breast cancer treatment trial
4/9/2024 - Proactive Investors - UK
Atossa Therapeutics presents data from 40mg cohort of Phase 2 EVANGELINE trial
4/9/2024 - The Fly
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
4/9/2024 - Globe Newswire
Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis
4/3/2024 - GuruFocus
Navigating Choppy Waters: Atossa Therapeutics' Struggle with Compliance Costs and Business Performance
4/3/2024 - TipRanks Financial Blog
Optimistic Outlook for Atossa Therapeutics' Z-endoxifen in Breast Density and Cancer Therapy
4/2/2024 - TipRanks Financial Blog
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
4/2/2024 - InvestorPlace
Atossa Therapeutics sets sights on breast cancer trial results after strong 4Q
4/1/2024 - Proactive Investors - UK
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4/1/2024 - Globe Newswire
Atossa Therapeutics provides five-year (Z)-endoxifen update
3/21/2024 - The Fly
Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasm
3/20/2024 - Proactive Investors - UK
Atossa Therapeutics back in Nasdaq's good graces
3/19/2024 - BizJournals.com - Nat'l Business News
Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifen
3/19/2024 - Proactive Investors - UK
Atossa Therapeutics provides five-year Z-Endoxifen treatment update
3/19/2024 - The Fly
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
3/19/2024 - Globe Newswire
Atossa Therapeutics regains compliance with Nasdaq minimum bid price rule
3/18/2024 - The Fly
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
3/18/2024 - Globe Newswire
Atossa Therapeutics adds breast cancer expert to board
3/12/2024 - Proactive Investors - UK
Atossa Therapeutics appoints Tessa Cigler to board of directors
3/12/2024 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$31.36M
EBIT (TTM)
-$31.38M
Net Income (TTM)
-$30.09M
Balance Sheet
Total Assets (Q)
$96.25M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$5.24M
Book Value Per Share (Q)
$0.7264
Cash Flow
Cash from Operations (TTM)
-$20.94M
Cash from Investing (TTM)
-$14.00K
Cash from Financing (TTM)
-$1.48M
Net Change in Cash (TTM)
-$22.43M
Filings
Filing Date
Monday, April 1, 2024
Period Date
Sunday, December 31, 2023
Next Filing
Week of May 13 and 17 (est)
Price History
Loading...
Beta
1.04
7-Day Total Return
-14.46%
30-Day Total Return
18.33%
60-Day Total Return
73.17%
90-Day Total Return
102.86%
Year to Date Total Return
51.87%
1-Year Total Return
111.31%
2-Year Total Return
35.24%
3-Year Total Return
-19.77%
5-Year Total Return
-59.20%
52-week Low
Apr 27, 2023 - $0.5901
52-week High
Apr 05, 2024 - $2.31
Valuation
Market Cap
$171.67M - Micro Cap
Enterprise Value
$83.21M
Price/Sales (TTM)
--
Price/Book (Q)
1.89
Dividends and Shares
Shares Outstanding
125.29M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.atossatherapeutics.com
Phone Number
206 588 0256
Address
107 Spring Street
Seattle, WA 98104
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions... more
NASDAQ 04/23/2024 11:21AM Eastern Quotes delayed
Weiss Ratings